✦ LIBER ✦

Short CommunicationsAssessment of blindness in the danish verapamil infarction trial II (DAVIT II)

✍ Scribed by C. M. Jespersen; the Danish Study Group on Verapamil in Myocardial Infarction

Book ID: 110609293
Publisher: Springer
Year: 1990
Tongue: English
Weight: 200 KB
Volume: 39
Category: Article
ISSN: 0031-6970
DOI: 10.1007/bf02657062

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Verapamil in Acute Myocardial Infarction

Verapamil in Acute Myocardial Infarction. The Rationales of the VAMI and DAVIT III Trials

✍ Christian M. Jespersen 📂 Article 📅 1999 🏛 Springer US 🌐 English ⚖ 96 KB

Erratum: Verapamil in Acute Myocardial I

Erratum: Verapamil in Acute Myocardial Infarction. The Rationales of the VAMI and DAVIT III Trials

✍ Christian M. Jespersen 📂 Article 📅 2000 🏛 Springer US 🌐 English ⚖ 101 KB

Role of ischemia in postinfarction heart

Role of ischemia in postinfarction heart failure: Hypothetical considerations based on use of verapamil in the DAVIT II study

✍ Christian M. Jespersen 📂 Article 📅 1994 🏛 Springer US 🌐 English ⚖ 500 KB

The Association of Anticoagulant Protein

The Association of Anticoagulant Protein Concentrations with Acute Myocardial Infarction in the Thrombolysis in Myocardial Infarction Phase II (TIMI II) Trial

✍ Peter W. Callas; Russell P. Tracy; Edwin G. Bovill; ChristopherBruce Cannon; Bru 📂 Article 📅 1998 🏛 Springer US 🌐 English ⚖ 144 KB

Abatacept in the treatment of patients w

Abatacept in the treatment of patients with psoriatic arthritis: Results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial

✍ Philip Mease; Mark C. Genovese; Geoffrey Gladstein; Alan J. Kivitz; Christopher 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 215 KB 👁 3 views

Efficacy and safety of rituximab in mode

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial

✍ Joan T. Merrill; C. Michael Neuwelt; Daniel J. Wallace; Joseph C. Shanahan; Kevi 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 499 KB 👁 2 views

## Abstract ## Objective B cells are likely to contribute to the pathogenesis of systemic lupus erythematosus (SLE), and rituximab induces depletion of B cells. The Exploratory Phase II/III SLE Evaluation of Rituximab (EXPLORER) trial tested the efficacy and safety of rituximab versus placebo in p